Abstract
Mutations that activate the small GTP-binding protein KRAS are the most common oncogenic event in human tumors. Thirty years after its discovery, mutant KRAS has yet to be therapeutically conquered.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Humans
-
Mutation
-
Neoplasms / drug therapy
-
Neoplasms / genetics*
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins / genetics*
Substances
-
Antineoplastic Agents
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins